Human midbrain organoids, which contain dopaminergic neurons, provide an effective screening platform for Parkinson’s disease (PD). Patient derived organoids carry relevant mutations, and present disease-relevant phenotypes. The platform is fully developed and has already resulted in a number of publications addressing molecular mechanisms of Parkinson’s disease.
InnoSer has joined forces with OrganoTherapeutics to make midbrain organoids available for screening and development of pharmaceutical compounds. This partnership enables providing midbrain organoids commercially as a platform for Parkinson’s disease research. OrganoTherapeutics founders Dr. Javier Jarazo and Dr. Jens Schwamborn are both experts in stem cell research and in-vitro modeling of Parkinson’s disease.
Prof. Dr. Jens Schwamborn
Involved in InnoSer’s Scientific Advisory Board, Dr. Schwamborn from University of Luxembourg focuses on linking the molecular function of Parkinson’s Disease-associated proteins with cell cycle progression, protein aggregation and mitochondrial / lysosomal function.